Lipoprotein(a) testing: what it measures and when to order.

What the test measures

Lp(a) is an LDL-like particle in which apolipoprotein B-100 is bound to a distinctive apolipoprotein(a). Plasma concentration is largely genetically determined and stays stable for most of adult life, so a single measurement usually characterizes a patient for years rather than months. Levels can rise with inflammation, kidney disease, and menopause, so a repeat measurement is reasonable when one of those changes the clinical picture.

The assay reports particle concentration. Results are expressed in nmol/L, which reflects particle number, or in mg/dL, which reflects mass on some older methods. Because particle size varies between individuals, nmol/L is generally preferred for comparing patients on a consistent scale.

When clinicians may consider ordering

Lp(a) is not part of a routine lipid panel, and because it is largely fixed, most patients need it only once unless a new clinical question arises or one of the conditions that can raise Lp(a) develops. Clinicians commonly consider it to refine risk in situations such as:

• a personal or family history of premature atherosclerotic cardiovascular disease;
• atherosclerotic disease that progresses despite well-managed LDL-C;
• a known family history of elevated Lp(a);
• borderline decisions where an added, independent risk marker would sharpen the picture.

Because concentration is inherited, an elevated result in one patient can prompt a conversation about testing first-degree relatives. Whether to pursue that is a clinical judgment for the provider.

Interpreting the result

The reference range applied by Quest Diagnostics’ national laboratory network is <75 nmol/L. Widely used cardiovascular guidelines set their risk threshold higher, at about 125 nmol/L (about 50 mg/dL), so a result between the two numbers is above the lab reference cut point but below the common guideline threshold. Values above the range are generally regarded as conferring incremental cardiovascular risk that tends to rise with concentration. Lp(a) is a risk marker rather than a diagnosis: it contextualizes global risk alongside the standard lipid panel, ApoB, and the clinical history.

A single value is usually sufficient given the stability of Lp(a) over most of adult life. Ordering, interpretation, and any resulting management remain the responsibility of the licensed provider, and nothing here is a treatment recommendation.

Practical notes for ordering

The test uses a serum specimen and does not require fasting, so it can ride along on any scheduled draw. Turnaround is typically several business days, so it fits naturally into a scheduled cardiovascular workup rather than a same-visit decision. Patients can complete the draw nationwide through a CLIA-certified laboratory network, and results return to the ordering provider for review.

Because Lp(a) rarely needs repeating, it pairs well with a one-time baseline risk assessment. For the broader lipid picture, ApoB is a natural companion measure; see the ApoB guide for how the two fit together.